Lonza Group stays busy making active ingredients. Spun off by Switzerland's former industrial giant Alusuisse Lonza Group (Algroup), Lonza Group is focused mostly on research and production for pharmaceutical and chemical firms. It is a contract manufacturer of the advanced intermediates and active ingredients used in drugs. Lonza also is active in biotechnology: It uses microbial fermentation and biotransformation to produce fine chemical intermediates and is involved in mammalian cell culture research. It also produces organic fine chemicals and performance chemicals (biocides and oleochemicals).

Arrow Therapeutics was founded in 1998; AstraZeneca acquired the firm in 2007. Arrow Therapeutics is a pharmaceutical product discovery company that is researching new anti-infective medicines. The company's top candidate is RSV604, an antiviral molecular program to combat respiratory syncytial virus (RSV), a leading cause of respiratory infections worldwide. This candidate is currently undergoing clinical trials and has been licensed to Novartis. Other leading programs include compounds developed to fight infectious dieseases such as Hepatitis C, herpes, and chicken pox.

Dechra lies down with dogs ... and cats and birds and horses too. Dechra Pharmaceuticals lays claim to being the only listed pharmaceutical company that makes most of its income from the animal health care market. The company manufactures and distributes veterinary pharmaceutical products and supplies internationally, mainly in the US and the UK. Its network of subsidiaries includes suppliers National Veterinary Services and Dechra Veterinary Products, manufacturer Dales Pharmaceuticals, and development companies North Western Laboratories and Cambridge Specialist Laboratory Services.

INC Research is a contract research organization (CRO) that specializes in conducting clinical trials for drugs targeting cancer, infectious diseases, and central nervous system disorders. It also has a division devoted to pediatrics. Its services include scientific and medical consulting, study monitoring, project management, and regulatory support services. The CRO operates in more than 30 countries around the globe. Its DataSpectrum subsidiary helps researchers capture and manage clinical trial data. The company was formed in 1998 as a result of the merger between the Neuroclinical Trials Center and the Integrated Neuroscience Consortium.

Santhera Pharmaceuticals Holding AG (Santhera) is a Swiss company focused on discovery, development and commercialization of small-molecule pharmaceutical products for the treatment of severe neuromuscular diseases. CATENA is Santhera’s first product approved in Canada for symptomatic treatment of Friedreich's ataxia. Santhera has five clinical-stage development programs, three of which investigate its core compound, SNT-MC17/idebenon, in the treatment of Friedreich’s ataxia, Duchenne muscular dystrophy and Leber’s hereditary optic neuropathy. Another clinical program investigates JP-1730/fipamezole in the treatment of dyskinesia in Parkinson’s disease. The fifth program concerns congenital muscular dystrophies. It operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, engaged in research and development of pharmaceuticals, Santhera Pharmaceuticals (Canada), Inc., active in marketing and sales of pharmaceuticals, and Santhera Pharmaceuticals (USA), Inc.

Diosynth Biotechnology is all about the cGMP and protein. The company is a leading provider of cGMP (Current Good Manufacturing Practices) production for recombinant therapeutic proteins and peptides. Diosynth's line of proteins include monoclonal antibodies, cancer vaccines, fusion proteins, hormones, cancer vaccines, and anti-coagulants. The company also offers contract manufacturing, process development, and validation services. Diosynth has manufacturing facilities in the US, serving a wide range of customers. The company (which originally began operating in 1923) was a subsidiary of Akzo Nobel until Schering-Plough bought that company's pharmaceutical operations in 2007.

Tercica, Inc. company was founded in 2002 and is based in Brisbane, California. As of October 16, 2008, Tercica Inc. operates as a subsidiary of Ipsen S.A. Tercica Inc., a biotechnology company, engages in the development and commercialization of therapeutics for the treatment of endocrine and metabolic diseases. Its products include Increlex, an rDNA origin injection for the long-term treatment of children with short stature due to severe primary IGFD; and Somatuline Depot, a lanreotide injection for the treatment of adults with acromegaly. Tercica Inc. has strategic partnerships with Genentech and Ipsen SA.

AAIPharma provides contract research services to the pharmaceutical, biotech, and medical device industries. Its outsourcing services run the gamut from drug candidate selection and feasibility studies, to bioanalytical testing and clinical trials management. Its early clinical development division helps evaluate potential compounds and design patient studies. The company's clinical development businesses run large clinical trials for customers around the world. Other services include regulatory support and data management. AAIPharma has divested its pharmaceutical development division, which cranked out small batches of drugs to supply clinical trials and develops oral drug delivery technology.

Curis, Inc. company was founded in 2000 and is based in Cambridge, Massachusetts. Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics. The company, in collaboration with Genentech, is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and in advanced ovarian cancer patients. It is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase (HDAC), epidermal growth factor receptor (EGFR), and epidermal growth factor receptor 2 (Her2). In addition, Curis has a development candidate, CUDC-305, a Heat Shock Protein 90 (Hsp90) inhibitor.

Kalypsys is searching for new medicines, and has developed a zippy way to find them. Its ultra-high throughput automated epiK screening system can analyze more than one million cell-based assay wells a day and can run 24 hours a day seven days a week. With that kind of research capability, the company has developed its own bioinformatics software to enable researchers to quickly find and compare data points. Kalypsys is generous enough to market the system, under the Kalypsys Systems brand, to other pharmaceutical research facilities. Its own drug development pipeline includes compounds in early stages of development, targeting cancer, inflammatory diseases, pain, and metabolic diseases.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.